Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kyprolis

- PMLiVE

Sanofi’s Darzalex rival scores in myeloma trial

Antibody first to show benefit in combination setting

- PMLiVE

Morphosys’ Darzalex patent challenge hits a hurdle

Genmab and J&J's myeloma drug is a blockbuster

- PMLiVE

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

BiTE will rival therapies from Bluebird, Celgene/Juno, J&J/Legend biotech

Celgene building

ASH18: CAR-T and drugs give new options for multiple myeloma

San Diego congress showcasing data in important haematology markets

- PMLiVE

FDA green lights BMS’ multiple myeloma combo

Speedy approval follows a breakthrough designation

- PMLiVE

FDA clears first-line use for J&J’s myeloma drug Darzalex

Frontline approval for Janssen's Darzalex a milestone in march towards blockbuster status

- PMLiVE

Janssen submits esketamine in Europe for treatment resistant depression

Fast-acting drug would be first new treatment for refractory disease in 50 years

- PMLiVE

Janssen’s single tablet Symtuza gains NHS England funding 

Janssen and Gilead combination first to reach patients

- PMLiVE

Darzalex powers ahead with frontline myeloma approval in Europe

New approval makes Darzalex first antibody drug approved in first line

- PMLiVE

Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator

A round-up from pharma, biotech and healthcare

- PMLiVE

Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices

The latest from pharma, biotech and healthcare

- PMLiVE

J&J moves quickly ahead with trials of myeloma CAR-T

Expects to start trials during the second half of this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links